KDIGO Updated Guidelines in Treatment of Membranous Nephropathy
I notice there appears to be a mismatch between your question about "KIDGO updated guidelines in ttt of MN" (which seems to refer to KDIGO guidelines for Membranous Nephropathy) and the evidence provided, which exclusively covers malaria treatment guidelines.
The evidence provided does not contain any information about KDIGO (Kidney Disease: Improving Global Outcomes) guidelines or membranous nephropathy treatment. All references 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 pertain exclusively to malaria diagnosis and treatment protocols.
What the Evidence Actually Addresses
The provided evidence comprehensively covers:
- Uncomplicated malaria treatment with artemisinin-based combination therapies (ACTs), specifically artemether-lumefantrine and dihydroartemisinin-piperaquine 2
- Severe malaria treatment with intravenous artesunate 2
- Special populations including pregnant women and patients with renal/hepatic impairment 1, 5
- Non-falciparum malaria treatment with chloroquine and primaquine 2, 7
To Properly Answer Your Question
To provide accurate information about KDIGO guidelines for membranous nephropathy treatment, I would need evidence that includes:
- KDIGO clinical practice guidelines for glomerular diseases
- Immunosuppressive therapy protocols (rituximab, cyclophosphamide, calcineurin inhibitors)
- Risk stratification criteria for membranous nephropathy
- Supportive care recommendations (RAAS blockade, anticoagulation thresholds)
Please clarify if you intended to ask about malaria treatment guidelines, or provide evidence related to KDIGO membranous nephropathy guidelines for an accurate response.